Abstract
Osteosarcoma (OS) is one of the most serious malignancies along with a high incidence in children and teenagers. Although the neoadjuvant chemotherapy of OS has made great progress and prolongs the five-year survival rates of patients to some extent, drugs are restrained from clinical application due to the unsatisfactory efficacy and severe side effects, especially for the systemic therapy through intravenous injection. The polymeric nanoparticles as anti-cancer drug nanocarriers make OS treatment more promising and effective. Specifically, various polymeric nanoparticles have been developed to overcome the difficulties in targeting delivery of drugs to OS tissue and/or cells through passive and/or active strategies. This review presents an overview on the development of polymeric nanoparticles for anti-cancer drug delivery in OS treatment, and briefly describes the challenge and opportunity for future development.
Keywords: Active targeting, controlled drug delivery, osteosarcoma therapy, passive targeting, polymeric nanocarriers.
Current Pharmaceutical Design
Title:Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment
Volume: 21 Issue: 36
Author(s): Xueyuan Gu, Jianxun Ding, Zhiyu Zhang, Qin Li, Xiuli Zhuang and Xuesi Chen
Affiliation:
Keywords: Active targeting, controlled drug delivery, osteosarcoma therapy, passive targeting, polymeric nanocarriers.
Abstract: Osteosarcoma (OS) is one of the most serious malignancies along with a high incidence in children and teenagers. Although the neoadjuvant chemotherapy of OS has made great progress and prolongs the five-year survival rates of patients to some extent, drugs are restrained from clinical application due to the unsatisfactory efficacy and severe side effects, especially for the systemic therapy through intravenous injection. The polymeric nanoparticles as anti-cancer drug nanocarriers make OS treatment more promising and effective. Specifically, various polymeric nanoparticles have been developed to overcome the difficulties in targeting delivery of drugs to OS tissue and/or cells through passive and/or active strategies. This review presents an overview on the development of polymeric nanoparticles for anti-cancer drug delivery in OS treatment, and briefly describes the challenge and opportunity for future development.
Export Options
About this article
Cite this article as:
Gu Xueyuan, Ding Jianxun, Zhang Zhiyu, Li Qin, Zhuang Xiuli and Chen Xuesi, Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment, Current Pharmaceutical Design 2015; 21 (36) . https://dx.doi.org/10.2174/1381612821666150923095618
DOI https://dx.doi.org/10.2174/1381612821666150923095618 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anticancer Advances of Matrine and Its Derivatives
Current Pharmaceutical Design Insights into Targeting Colon Cancer Cell Fate at the Level of Proteoglycans / Glycosaminoglycans
Current Medicinal Chemistry Effects of Drug Transporters on Pharmacological Responses and Safety
Current Drug Metabolism Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review
Current Medicinal Chemistry Molecular Mechanisms of Thymoquinone as Anticancer Agent
Combinatorial Chemistry & High Throughput Screening Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?
Recent Patents on Anti-Cancer Drug Discovery Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy
Current Medicinal Chemistry Osteoporosis and its Association with Non-Gonadal Hormones Involved in Hypertension, Adiposity and Hyperglycaemia
Current Drug Targets The Current and Future Therapies for Human Osteosarcoma
Current Cancer Therapy Reviews Regulatory Influence of Scaffolds on Cell Behavior: How Cells Decode Biomaterials
Current Pharmaceutical Biotechnology Single-Photon Emission Computed Tomography Tracers for Predicting and Monitoring Cancer Therapy
Current Pharmaceutical Biotechnology Bladder Cancer: A Simple Model Becomes Complex
Current Genomics The Potential Anti-Tumorigenic and Anti-Metastatic Side of the Proprotein Convertases Inhibitors
Recent Patents on Anti-Cancer Drug Discovery The Chlorophyll Catabolite Pheophorbide a as a Photosensitizer for the Photodynamic Therapy
Current Medicinal Chemistry Implication of Prophetic Variables and their Impulsive Interplay in CA Prostate Patients Experiencing Osteo-Metastasis
Anti-Cancer Agents in Medicinal Chemistry Effects of Agaricus Blazei Extract Plus Lactoferrin or Lactoferrin Alone on Tumor Growth and UFT-Induced Adverse Reactions in Sarcoma 180- or Highly Metastatic Osteosarcoma LM8-Bearing Mice
The Natural Products Journal